Ignite Creation Date:
2025-12-18 @ 8:20 AM
Ignite Modification Date:
2025-12-18 @ 8:20 AM
Study NCT ID:
NCT04640623
Status:
None
Last Update Posted:
2025-12-05 00:00:00
First Post:
2020-11-20 00:00:00
Is Possible Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
Sponsor:
None
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-12-18
Start Date Type:
ACTUAL
Primary Completion Date:
2025-07-03
Primary Completion Date Type:
ACTUAL
Completion Date:
2027-09-30
Completion Date Type:
ESTIMATED
First Submit Date:
2020-11-20 00:00:00
First Submit QC Date:
None
Study First Post Date:
2020-11-23
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-04 00:00:00
Last Update Post Date:
2025-12-05 00:00:00
Last Update Post Date Type:
ESTIMATED